ETON SEC-Einreichungen - Eton Pharmaceuticals, Inc.- Jahresbericht, Proxy Statement, Prospekt

Basisstatistiken

CIK

1710340

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Eton Pharmaceuticals, Inc.

SEC Filings (Chronological Order)

Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.

May 19, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 18, 2026 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 18, 2026 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) File
May 19, 2026	EX-99.1	Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine) Exhibit 99.1 NOT FOR IMMEDIATE RELEASE Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine) ● IMPAVIDO® is the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis caused by specific Leishmania species ● Leishmaniasis is a rare but potentially life-threatening parasitic disease that
May 14, 2026	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38738 ETON PHAR
May 14, 2026	EX-99.1	Eton Pharmaceuticals Reports First Quarter 2026 Financial Results Exhibit 99.1 Eton Pharmaceuticals Reports First Quarter 2026 Financial Results ● Q1 2026 product sales of $24.3 million, representing 73% growth over Q1 2025 ● Raising full year revenue guidance - now expect 2026 revenue to exceed $120 million, up from previous guidance of $110 million ● Q1 2026 fully diluted GAAP EPS of $0.05, non-GAAP fully diluted EPS of $0.14, and Adjusted EBITDA of $5.7 milli
May 14, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 14, 2026 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 14, 2026 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State (Commission (I.R.S. Employer of incorporation) File
May 14, 2026	EX-10.1	EXCLUSIVE LICENSE AGREEMENT Exhibit 10.1 Docusign Envelope ID: 855DD667-C5DE-4441-8AAF-142393CE74B1 PFM #2026-00074 Certain information has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential EXCLUSIVE LICENSE AGREEMENT THIS EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) dated as of February 27, 2026 (the “Effective Date”), is entered into betwe
May 1, 2026	EX-99.1	Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution Exhibit 99.1 Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution ● HEMANGEOL is now available exclusively through Anovo Specialty Pharmacy to streamline access and therapy initiation ● Eton has integrated full Eton Cares patient support, including $0 co-pay for eligible commercially insured patients and expanded patie
May 1, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 1, 2026 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 1, 2026 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) File N
April 27, 2026	EX-99.1	Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700 Exhibit 99.1 Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700 ● Company’s extended-release formulation of zinc acetate will be compared to GALZIN® (zinc acetate) and a placebo for the treatment of Wilson disease DEER PARK, Ill., April 27, 2026 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical
April 27, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 27, 2026 Date of Report (Date of earliest event reported) ETON PHARMACEUTICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 27, 2026 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) Fil
April 24, 2026	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini
April 16, 2026	EX-99.1	Eton Pharmaceuticals Announces CFO Succession Plan Exhibit 99.1 Eton Pharmaceuticals Announces CFO Succession Plan ● Experienced pharmaceutical executive Judith M. Matthews to assume CFO role on June 1st DEER PARK, Ill., April 16, 2026 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced th
April 16, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 16, 2026 Date of Report (Date of earliest event reported) ETON PHARMACEUTICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 16, 2026 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) Fil
April 15, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 9, 2026 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 9, 2026 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) File
April 15, 2026	EX-10.1	SIXTH AMENDMENT TO CREDIT AGREEMENT Exhibit 10.1 SIXTH AMENDMENT TO CREDIT AGREEMENT THIS SIXTH AMENDMENT TO CREDIT AGREEMENT (this “Amendment”), dated as of April 9, 2026, is entered into by and among ETON PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), each of the undersigned financial institutions (individually each a “Lender” and collectively “Lenders”), SWK FUNDING LLC, a Delaware limited liability company, in its c
March 19, 2026	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38738 ETON PHARMACEUT
March 19, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 19, 2026 Date of Report (Date of earliest event reported) ETON PHARMACEUTICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 19, 2026 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State (Commission (I.R.S. Employer of incorporation) Fil
March 19, 2026	EX-99.1	Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results Exhibit 99.1 Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results ● Q4 2025 product sales of $21.3 million, representing 83% growth over Q4 2024 ● Q4 2025 basic GAAP EPS of $0.06, fully diluted GAAP EPS of $0.05, basic non-GAAP EPS of $0.21, fully diluted non-GAAP EPS of $0.19, and Adjusted EBITDA of $6.2 million ● Launched DESMODA™, the first and only FDA-approved desm
March 19, 2026	EX-97	Eton Pharmaceuticals, Inc. Clawback Policy Exhibit 97 Eton Pharmaceuticals, Inc. Clawback Policy Introduction The Board of Directors (the “Board”) of Eton Pharmaceuticals, Inc. (the “Company”) believes that it is in the best interests of the Company and its stockholders to adopt a policy that reflects that portion of the Company’s compensation philosophy related to incentive compensation. The Board has therefore adopted this policy which p
March 6, 2026	EX-FILING FEES	Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 Eton Pharmaceuticals, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, par value $0.001 per share, Eton Pharmaceuticals, Inc. 2018 Equity Incentive Plan Other 1,08
March 6, 2026	S-8	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 Eton Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 Eton Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 37-1858472 (I.R.S. Employer Identification No.) 21925 W. Field Parkway, Suite 235 Deer
March 2, 2026	EX-99.1	Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution Exhibit 99.1 NOT FOR IMMEDIATE RELEASE Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution ● HEMANGEOL® is the only FDA-approved treatment for infantile hemangioma ● HEMANGEOL will be commercialized by Eton beginning May 1st ● HEMANGEOL will be distributed through the company’s Eton Cares™
March 2, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 27, 2026 Date of Report (Date of earliest event reported) ETON PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 27, 2026 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation)
February 25, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 25, 2026 Date of Report (Date of earliest event reported) ETON PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 25, 2026 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation)
February 25, 2026	EX-99.1	Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution Exhibit 99.1 Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution ● DESMODA is the first and only FDA-approved desmopressin oral solution ● Commercial launch expected on March 9th ● DESMODA eliminates tablet splitting and crushing, enabling precise, individualized dosing for patients of all ages ● The product is expected to be a significant long-term g
February 2, 2026	EX-99.1	Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate Exhibit 99.1 Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate ● Product is currently under review with the FDA ● Potential approval and launch mid-2026 DEER PARK, Ill., FEB 2, 2026 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare disease
February 2, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 02, 2026 Date of Report (Date of earliest event reported) ETON PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 02, 2026 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation)
December 4, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 4, 2025 Date of Report (Date of earliest event reported) ETON PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 4, 2025 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State (Commission (I.R.S. Employer of incorporation) F
December 4, 2025	EX-99.1	EXHIBIT 99.1 Exhibit 99.1
November 19, 2025	S-8	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 Eton Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 Eton Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 37-1858472 (I.R.S. Employer Identification No.) 21925 W. Field Parkway, Suite 235 Deer
November 19, 2025	EX-FILING FEES	Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 Eton Pharmaceuticals, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, par value $0.001 per share, Eton Pharmaceuticals, Inc. 2018 Equity Incentive Plan Other 1,06
November 18, 2025	EX-99.2	UNAUDITED PROFORMA CONDENSED COMBINED FINANCIAL STATEMENTS Exhibit 99.2 UNAUDITED PROFORMA CONDENSED COMBINED FINANCIAL STATEMENTS On October 2, 2024, Eton Pharmaceuticals, Inc. (the "Company or Eton") and Ipsen Biopharmaceuticals, Inc. (“Ipsen”), a subsidiary of Ipsen S.A., entered into an Asset Purchase Agreement (the “Acquired INCRELEX® Product”), whereby the Company agreed to acquire Increlex® (mecasermin injection) from Ipsen. Increlex® is a biologic
November 18, 2025	EX-99.1	ACQUIRED INCRELEX® PRODUCT ABBREVIATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2023 AND 2022 AND FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022 (Audited) AS OF SEPTEMBER 30, 2024 (Unaudited) AND FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023 ( Exhibit 99.1 ACQUIRED INCRELEX® PRODUCT ABBREVIATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2023 AND 2022 AND FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022 (Audited) AS OF SEPTEMBER 30, 2024 (Unaudited) AND FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023 (Unaudited) ACQUIRED INCRELEX® INDEX TO ABBREVIATED FINANCIAL STATEMENTS Report of Independent Certified Public Accountants 1 Abbreviated
November 18, 2025	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 19, 2024 Date of Report (Date of earliest event reported) ETON PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 19, 2024 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation
November 6, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 6, 2025 Date of Report (Date of earliest event reported) ETON PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 6, 2025 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State (Commission (I.R.S. Employer of incorporation) F
November 6, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38738 ETON
November 6, 2025	EX-99.1	Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results Exhibit 99.1 Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results ● Q3 2025 product sales of $22.5 million, representing 129% growth over Q3 2024 and the 19th straight quarter of sequential product sales growth ● Q3 2025 basic and fully diluted GAAP EPS of $(0.07), non-GAAP fully diluted EPS of $0.04, and Adjusted EBITDA of $2.9 million ● ET-600 NDA accepted for review, assigned PDUFA
August 7, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38738 ETON PHARM
August 7, 2025	EX-10.3	Amended Offer Letter Agreement by and between the Registrant and James Gruber, dated as of June 27, 2022. Exhibit 10.3 ETON PHARMACEUTICALS, INC. 21925 W. Field Parkway, Suite 235 Deer Park, IL 60010-7278 March 18, 2022 (amended June 30, 2025 for change in severance provision) Re: Employment Terms Dear James: On behalf of Eton Pharmaceuticals, Inc. (the “Company”), I am pleased to offer you employment in the position of Chief Financial Officer of the Company, on the terms set forth in this offer lette
August 7, 2025	EX-10.1	Amended Offer Letter Agreement by and between the Registrant and Sean Brynjelsen, dated as of June 27, 2022. Exhibit 10.1 ETON PHARMACEUTICALS, INC. 12264 El Camino Real, Suite 350 San Diego, CA 92130 May 14, 2017 (as amended June 30, 2025 for change in severance provisions) Re: Employment Terms Dear Sean: On behalf of Eton Pharmaceuticals, Inc. (the “Company”), I am pleased to offer you employment in the position of Chief Executive Officer of the Company, on the terms set forth in this offer letter agre
August 7, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 7, 2025 Date of Report (Date of earliest event reported) ETON PHARMACEUTICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 7, 2025 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State (Commission (I.R.S. Employer of incorporation) Fil
August 7, 2025	EX-10.2	Amended Offer Letter Agreement by and between the Registrant and David Krempa, dated as of June 27, 2022. Exhibit 10.2 ETON PHARMACEUTICALS, INC. 21925 Field Parkway Suite 235 Deer Park, IL 60010 August 2, 2017 David Krempa (amended June 30, 2025 for change in severance position) Re: Employment Terms Dear David: On behalf of Eton Pharmaceuticals, Inc. (the “Company”), I am pleased to offer you employment in the position of Executive Director, Business Development of the Company, on the terms set forth
August 7, 2025	EX-99.1	Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results Exhibit 99.1 Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results ● Q2 2025 product sales of $18.9 million, representing 108% growth over Q2 2024 and the 18th straight quarter of sequential product sales growth ● Q2 2025 basic and fully diluted GAAP EPS of $(0.10), non-GAAP fully diluted EPS of $0.03, and Adjusted EBITDA of $3.1 million ● Launched KHINDIVI™ (hydrocortisone) Oral Solu
August 7, 2025	EX-10.4	Amended Offer Letter Agreement by and between the Registrant and Ipek Erdogan-Trinkaus, dated as of June 27, 2022. Exhibit 10.4 ETON PHARMACEUTICALS, INC. 21925 W. Field Parkway, Suite 235 Deer Park, IL 60010-7278 November 6, 2024 (amended June 30, 2025 for change in severance provision) Re: Employment Terms Dear Ipek: On behalf of Eton Pharmaceuticals, Inc. (the “Company”), I am pleased to offer you employment in the position of Chief Commercial Officer of the Company, on the terms set forth in this offer let
July 8, 2025	EX-99.1	Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution) - NDA assigned a Target Action Date of February 25, 2026 - - Product has patent protection through 2044 - Exhibit 99.1 Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution) - NDA assigned a Target Action Date of February 25, 2026 - - Product has patent protection through 2044 - DEER PARK, Ill., July 08, 2025 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on devel
July 8, 2025	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 08, 2025 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) File
June 27, 2025	EX-99.1	Eton Pharmaceuticals Announces Addition to Russell 2000 Exhibit 99.1 Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes DEER PARK, Ill., June 27, 2025 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will be added to the broad-market Russell 3000® and s
June 27, 2025	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 27, 2025 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) File
June 20, 2025	EX-16.1	Letter from Crowe LLP, dated June 20, 2025 Exhibit 16.1 June 20, 2025 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, N. E. Washington, D.C. 20549 Ladies and Gentlemen: We have read Eton Pharmaceuticals, Inc.’s statements included under Item 4.01(a) of Form 8-K of Eton Pharmaceuticals, Inc. filed on June 20, 2025, and are in agreement with such statements as they relate to us, except that we are not in a pos
June 20, 2025	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 13, 2025 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) File
June 10, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 10, 2025 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 10, 2025 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) File
May 28, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 28, 2025 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 28, 2025 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) File
May 28, 2025	EX-99.1	Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral Solution Exhibit 99.1 Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral Solution ● KHINDIVI is the first and only FDA-approved hydrocortisone oral solution ● Commercial launch expected the week of June 2nd ● Eton expects combined peak sales of KHINDIVI and ALKINDI SPRINKLE® (hydrocortisone) oral granules to exceed $50 million DEER PARK, Ill., MAY 28, 2025 (GLOBE NEWSWIRE)
May 13, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38738 ETON PHAR
May 13, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 13, 2025 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State (Commission (I.R.S. Employer of incorporation) File
May 13, 2025	EX-99.1	Eton Pharmaceuticals Reports First Quarter 2025 Financial Results Exhibit 99.1 Eton Pharmaceuticals Reports First Quarter 2025 Financial Results ● Q1 2025 revenue of $17.3 million, with product sales of $14.0 million, representing 76% growth over Q1 2024 and the 17th straight quarter of sequential product sales growth ● Q1 2025 basic and fully diluted GAAP EPS of $(0.06), Non-GAAP fully diluted EPS of $0.07, and Adjusted EBITDA of $3.7 million ● Relaunched pedia
May 2, 2025	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 19, 2024 Date of Report (Date of earliest event reported) ETON PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 19, 2024 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation
April 28, 2025	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 28, 2025 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) Fil
April 28, 2025	EX-99.1	Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution) Exhibit 99.1 Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution) ● NDA submitted for the treatment of central diabetes insipidus ● Expected 10-month review; commercial preparations underway for a potential Q1 2026 launch DEER PARK, Ill., April 28, 2025 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceu
April 25, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini
April 1, 2025	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 31, 2025 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) Fil
April 1, 2025	EX-99.1	Eton Pharmaceuticals Out-Licenses International Rights to Increlex Exhibit 99.1 Eton Pharmaceuticals Out-Licenses International Rights to Increlex® ● Esteve Pharmaceuticals, S.A. will commercialize Increlex in all markets outside the U.S. DEER PARK, Ill., April 1, 2025 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, t
March 18, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 18, 2025 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State (Commission (I.R.S. Employer of incorporation) Fil
March 18, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 18, 2025 Date of Report (Date of earliest event reported) ETON PHARMACEUTICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 18, 2025 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State (Commission (I.R.S. Employer of incorporation) Fil
March 18, 2025	EX-97	Policy Relating to Recovery of Erroneously Awarded Compensation Exhibit 97 Eton Pharmaceuticals, Inc. Clawback Policy Introduction The Board of Directors (the “Board”) of Eton Pharmaceuticals, Inc. (the “Company”) believes that it is in the best interests of the Company and its stockholders to adopt a policy that reflects that portion of the Company’s compensation philosophy related to incentive compensation. The Board has therefore adopted this policy which p
March 18, 2025	EX-10.11	Asset Purchase Agreement by and between the Company and Ipsen Biopharmaceuticals, Inc., dated as of October 2, 2024 (portions of the exhibit have been redacted). Exhibit 10.11 Certain information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential Execution Version ASSET PURCHASE AND SALE AGREEMENT Between IPSEN BIOPHARMACEUTICALS, INC. AND ETON PHARMACEUTICALS, INC. 1 List of Exhibits, Schedules and Seller Disclosure Schedule Exhibits: Exhibit A: Form of Assignment & Ass
March 18, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38738 ETON PHARMACEUT
March 18, 2025	EX-10.14	Licensing Agreement by and between the Company and AMMTek dated as of November 22, 2024. Exhibit 10.14 LICENCE AGREEMENT Dated as of November 21, 2024 (the “Effective Date”) BY AND BETWEEN: AMMTeK, a limited company incorporated under the laws of France, Paris Registrar, number 502 864 598, whose registered office is 15 rue Armand Carrel, Paris 75019, represented by its Chief Executive Officer, Paul Czernichow, hereafter referred to as Ammtek, on the first part, AND: Eton Pharmaceutic
March 18, 2025	EX-99.1	Eton Pharmaceuticals, Inc. STATEMENTS OF OPERATIONS (In thousands, except per share amounts) EX-99.1 2 ex786379.htm EXHIBIT 99.1 Exhibit 99.1 Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results Management to Hold Investor Day Conference Call Today at 10:00am ET ● Reported record product revenue of $11.6 million in Q4 2024, an increase of 59% over Q4 2023, representing the 16th straight quarter of sequential product sales growth ● Closed the transformational acquisition of p
March 18, 2025	EX-99.1	Eton Pharmaceuticals, Inc. Corporate Presentation March 18, 2025 Exhibit 99.1
March 14, 2025	EX-99.1	Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600 Exhibit 99.1 Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600 ● Company’s patented desmopressin oral solution successfully passed pivotal bioequivalence study ● Company expects to submit New Drug Application (NDA) in April 2025 DEER PARK, Ill., March 14, 2025 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an
March 14, 2025	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 14, 2025 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) Fil
March 7, 2025	8-K/A	Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 19, 2024 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation
March 3, 2025	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 3, 2025 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) File
March 3, 2025	EX-99.1	Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules Exhibit 99.1 Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules ● Eton expects to significantly expand patient access to this critical treatment for Wilson disease patients ● $0 co-pay for all eligible patients and best-in-class patient support services ● Now available exclusively through Optime Care DEER PARK, Ill., Mar. 03, 2025 (GLOBE NEWSWIRE) - Eton Pharmaceut
February 14, 2025	EX-99.1 AGREEMENT	AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G EX-99.1 AGREEMENT 2 exh99.htm EXHIBIT 99.1 AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934
February 7, 2025	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 7, 2025 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) F
February 7, 2025	EX-99.1	Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600 Exhibit 99.1 Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600 ● Product has patent protection through 2044 ● Expected to be listed in the U.S. Food and Drug Administration's (FDA) Orange Book upon the product's approval DEER PARK, Ill., February 7, 2025 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative phar
February 6, 2025	EX-99.1	Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400 Exhibit 99.1 Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400 DEER PARK, Ill., February 6, 2025 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Pres
February 6, 2025	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 6, 2025 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) F
January 3, 2025	EX-10.1	Asset Purchase Agreement dated December 31, 2024 between Teva Pharmaceuticals USA, Inc. and the Registrant (portions of the Exhibit have been redacted). Exhibit 10.1 Certain information has been redacted from this exhibit because it is both not material and is the type that the Registrant treats as private or confidential ASSET PURCHASE AGREEMENT THIS ASSET PURCHASE AGREEMENT (this “Agreement”) is effective as of the latest date set forth on the signature page hereto (the “Effective Date”), by and between Teva Pharmaceuticals USA, Inc., a Delaware
January 3, 2025	EX-99.1	Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin Exhibit 99.1 Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin® ● Adds an additional commercial and strategic rare disease product to Eton’s portfolio ● Galzin® is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease DEER PARK, Ill., Jan. 3, 2025 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasda
January 3, 2025	8-K	Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 31, 2024 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation)
December 20, 2024	8-K	Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 19, 2024 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation)
December 20, 2024	EX-99.1	Eton Pharmaceuticals Closes Acquisition of Increlex Exhibit 99.1 Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection) ● Acquisition bolsters Eton’s commercial pediatric endocrinology portfolio ● Product is now available through AnovoRx, a specialty pharmacy dedicated to serving patients with rare and chronic conditions DEER PARK, Ill., December 20, 2024 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (N
December 17, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 17, 2024 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation)
December 17, 2024	EX-99.1	Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical Trial Exhibit 99.1 Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical Trial Clinical Trial Demonstrates Clinical and Statistical Improvement in Metabolic Control During Prolonged Fasting in PKU Patients - Results Expected to Promote Awareness and Adoption of PKU GOLIKE® DEER PARK, Ill., December 17, 2024 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: E
December 12, 2024	EX-10.1	Form of Purchase Agreement Exhibit 10.1 FORM OF SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of December [●], 2024 by and between Eton Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the purchaser identified on the signature page hereto (the “Purchaser”). Preliminary Statement WHEREAS, subject to the terms and conditions set forth in this
December 12, 2024	424B5	Eton Pharmaceuticals, Inc. 583,334 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-271196 PROSPECTUS SUPPLEMENT (To the Prospectus Dated May 2, 2023) Eton Pharmaceuticals, Inc. 583,334 Shares of Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering in a registered direct offering to an institutional investor, 583,334 shares (the “Shares”) of our common stock at a purchase price o
December 12, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 10, 2024 Date of Report (Date of earliest event reported) ETON PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 10, 2024 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation)
December 9, 2024	SC 13G	ETON / Eton Pharmaceuticals, Inc. / EcoR1 Capital, LLC Passive Investment SC 13G 1 eton13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Eton Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29772L108 (CUSIP Number) December 2, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriat
December 3, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 3, 2024 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) F
December 3, 2024	EX-99.1	Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer Exhibit 99.1 Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer ● Ms. Erdogan-Trinkaus brings a wealth of commercial leadership and expertise in sales and marketing from her tenure at leading global pharmaceutical companies and across the broader health and wellness sector, including significant experience in the pediatric endocrinology specialty. DEER PARK, Ill., Dece
November 25, 2024	EX-99.1	Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension) Exhibit 99.1 Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension) ● Amglidia® has been approved by the European Medicines Agency (EMA) and is commercially available in Europe ● Strong strategic fit with Eton’s existing pediatric endocrinology focus ● Amglidia has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) ● Poten
November 25, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 22, 2024 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation)
November 12, 2024	EX-10.1	Fifth Amendment to Credit Agreement by and among the Company and SWK Funding LLC dated as of September 30, 2024 Exhibit 10.1 FIFTH AMENDMENT TO CREDIT AGREEMENT THIS FIFTH AMENDMENT TO CREDIT AGREEMENT (this “Amendment”), dated as of September 30, 2024, is entered into by and among ETON PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), each of the undersigned financial institutions (individually each a “Lender” and collectively “Lenders”), SWK FUNDING LLC, a Delaware limited liability company, in
November 12, 2024	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 12, 2024 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation)
November 12, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe
November 12, 2024	EX-99.1	Eton Pharmaceuticals, Inc. Condensed Statements of Operations (In thousands, except per share amounts) Exhibit 99.1 Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results ● Reported total revenue of $10.3 million and GAAP Net Income of $0.6 million or $0.02 per diluted share ● Entered into an asset purchase agreement to acquire Increlex® (mecasermin injection) ● Q3 2024 product sales increased 40% over Q3 2023, representing 15th straight quarter of sequential product sales growth ● Produ
November 12, 2024	EX-10.2	Second Amendment to Warrant Agreement by and among the Company and SWK Funding LLC dated as of September 30, 2024 Exhibit 10.2 THIS WARRANT AND THE SECURITIES ISSUED HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF (1) AN EFFECTIVE REGISTRATION STATEMENT COVERING SUCH SECURITIES UNDER THE SECURITIES ACT AND ANY OTHER APPLICABLE SECURI
November 7, 2024	EX-99.1	Eton Pharmaceuticals Awarded Second Patent for ET-400 (Hydrocortisone Oral Solution) Exhibit 99.1 Eton Pharmaceuticals Awarded Second Patent for ET-400 (Hydrocortisone Oral Solution) ● Product has patent protection through 2043 ● Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2025 DEER PARK, Ill., November 7, 2024 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on develop
November 7, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 5, 2024 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) F
October 3, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 2, 2024 Date of Report (Date of earliest event reported) ETON PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 2, 2024 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) Fi
October 3, 2024	EX-99.1	Eton Pharmaceuticals, Inc to Acquire Increlex Exhibit 99.1 Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen ● Aligns with Eton's Mission to Develop and Distribute Medicines that Have a Life Changing Impact for Patients with Ultra-rare Conditions ● Acquisition to Bolster Eton’s Commercial Pediatric Endocrinology Portfolio DEER PARK, Ill., Oct. 03, 2024 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (“Eton” or “the
September 12, 2024	SC 13G/A	ETON / Eton Pharmaceuticals, Inc. / Opaleye Management Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 7)* ETON PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29772L108 (CUSIP Number) James Silverman, One Boston Place, 26th Floor, Boston, MA 02108 (Name, Address and Telephone Number of Person A
August 8, 2024	EX-99.1	Eton Pharmaceuticals, Inc. Condensed Statements of Operations (In thousands, except per share amounts) Exhibit 99.1 Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results ● Product sales and royalty revenue of $9.1 million, representing 40% growth over Q2 2023 and the 14th straight quarter of sequential product sales growth ● New drug application (NDA) for ET-400 accepted by the U.S. Food and Drug Administration (FDA) and assigned a February 28, 2025 PDUFA date ● Q2 2024 Cash Flow from
August 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00
August 8, 2024	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 8, 2024 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) Fil
August 2, 2024	8-K/A	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 11, 2024 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) Fi
July 15, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 15, 2024 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 15, 2024 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) File
July 15, 2024	EX-99.1	Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution) Exhibit 99.1 Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution) ● Prescription Drug User Fee Act (PDUFA) target action date is February 28, 2025 ● Product has patent protection through 2043 DEER PARK, Ill., July 15, 2024 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical co
June 21, 2024	EX-99.1	June 21, 2024 Exhibit 16.1 June 21, 2024 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, N. E. Washington, D.C. 20549 Ladies and Gentlemen: We have read the comments made regarding us in Item 4.01 of Form 8-K of Eton Pharmaceuticals, Inc. dated June 14, 2024, and are in agreement with those statements. /s/ KMJ Corbin & Company LLP Irvine, California
June 21, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 14, 2024 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) File
June 11, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 11, 2024 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) File
May 9, 2024	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 9, 2024 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) File N
May 9, 2024	EX-99.1	Eton Pharmaceuticals, Inc. Statements of Operations (In thousands, except per share amounts) Exhibit 99.1 Eton Pharmaceuticals Reports First Quarter 2024 Financial Results ● Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13th straight quarter of sequential product sales growth ● Acquired PKU GOLIKE®, launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET-400 ● Management to hold conference call today at 4:30pm ET DEER PARK,
May 9, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0
April 30, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 30, 2024 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) Fil
April 30, 2024	SC 13D/A	ETON / Eton Pharmaceuticals, Inc. / Imprimis Pharmaceuticals, Inc. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Eton Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 29772L 108 (CUSIP Number) Harrow, Inc. 102 Woodmont Blvd., Suite 610 Nashville, Tennessee 37215 Attention: Andrew R. Boll (615) 733-4731 (Name, Ad
April 30, 2024	EX-99.1	Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution) Exhibit 99.1 Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution) ● Company anticipates 10-month review for potential approval in Q1 2025 ● Eton expects ET-400 and Alkindi Sprinkle® to achieve potential combined peak sales of more than $50 million annually ● Product has patent protection through 2043 DEER PARK, Ill., April 30, 2024 (GLO
April 26, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
April 18, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 15, 2024 Date of Report (Date of earliest event reported) ETON PHARMACEUTICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 15, 2024 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) Fil
March 26, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type) Eton Pharmaceuticals, Inc.
March 26, 2024	S-8	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 Eton Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) S-8 1 eton20240321cs8.htm FORM S-8 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 Eton Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 37-1858472 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 2192
March 22, 2024	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 -12-31FY2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File
March 22, 2024	EX-99.1	Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE Exhibit 99.1 Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria ● PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call point ● Transaction is expected to be accretive to 2024 earnings ● Estimated peak sales of more than $10 million annually ● U.S. phenylketonuria (“PKU”) medical formula mar
March 22, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 22, 2024 Date of Report (Date of earliest event reported) ETON PHARMACEUTICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 22, 2024 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State (Commission (I.R.S. Employer of incorporation) Fil
March 14, 2024	EX-19.1	Insider Trading Policy Exhibit 19.1 Insider Trading Policy (Revised December 2023) I. Purpose Anyone who has knowledge of material nonpublic information may be considered an “Insider” for purposes of the federal securities laws prohibiting insider trading. As an officer, director, or employee of Eton Pharmaceuticals, Inc. (the “Company”) you may be in a position to profit financially from buying, selling or dealing stoc
March 14, 2024	EX-97	Policy Relating to Recovery of Erroneously Awarded Compensation Exhibit 97 Eton Pharmaceuticals, Inc. Clawback Policy Introduction The Board of Directors (the “Board”) of Eton Pharmaceuticals, Inc. (the “Company”) believes that it is in the best interests of the Company and its stockholders to adopt a policy that reflects that portion of the Company’s compensation philosophy related to incentive compensation. The Board has therefore adopted this policy which p
March 14, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 14, 2024 Date of Report (Date of earliest event reported) ETON PHARMACEUTICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 14, 2024 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State (Commission (I.R.S. Employer of incorporation) Fil
March 14, 2024	EX-99.1	Eton Pharmaceuticals, Inc. STATEMENTS OF OPERATIONS (In thousands, except per share amounts) Exhibit 99.1 Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results ● Q4 2023 revenue of $7.3 million, representing a 109% increase from Q4 2022, marking the twelfth consecutive quarter of sequential product sales growth ● Full year 2023 revenues reached $31.6 million with product sales and royalty revenues of $26.1 million, a 132% increase from 2022 ● Announced successfu
March 14, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-387
February 21, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 21, 2024 Date of Report (Date of earliest event reported) ETON PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 21, 2024 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation)
February 21, 2024	EX-99.1	Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation Exhibit 99.1 Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation DEER PARK, Ill., Feb. 21, 2024 (GLOBE NEWSWIRE) - Eton Pharmaceuticals (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the United States Patent and Trademark Office ("
February 9, 2024	SC 13G/A	ETON / Eton Pharmaceuticals, Inc. / Opaleye Management Inc. Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* ETON PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29772L108 (CUSIP Number) James Silverman, One Boston Place, 26th Floor, Boston, MA 02108 (Name, Address and Te
February 2, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 2, 2024 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State (Commission (I.R.S. Employer of incorporation) F
February 2, 2024	EX-99.1	Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules Exhibit 99.1 Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules ● Eton Cares patient support program offers $0 co-pay to eligible, commercially insured patients* ● Current Nitisinone market is estimated to exceed $50 million annually ● Product is now available exclusively through Optime Care DEER PARK, Ill., Feb. 2, 2024 (GLOBE NEWSWIRE) - Eton
November 9, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 9, 2023 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State (Commission (I.R.S. Employer of incorporation) F
November 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe
November 9, 2023	EX-99.1	Eton Pharmaceuticals, Inc. Condensed Statements of Operations (In thousands, except per share amounts) Exhibit 99.1 Eton Pharmaceuticals Reports Third Quarter 2023 Financial Results ● Product sales and royalty revenue of $7.0 million up 118% from Q3 2022, representing the eleventh straight quarter of sequential product sales and royalty revenue growth ● Generated $0.9 million in positive cash flow from operations; ended quarter with $22.1 million of cash on hand ● Acquired ultra-rare disease produc
October 4, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 4, 2023 Date of Report (Date of earliest event reported) ETON PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 4, 2023 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State (Commission (I.R.S. Employer of incorporation) Fi
October 4, 2023	EX-99.1	Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone Exhibit 99.1 Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone ● Expect Q1 2024 product launch ● Nitisinone market estimated to be more than $50 million annually ● Eton will offer Eton Cares support program to all patients DEER PARK, Ill., Oct. 4, 2023 (GLOBE NEWSWIRE) - Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative phar
August 10, 2023	10-Q	UNITED STATES- SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES- SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 Eton Pharmaceutic UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 Eton Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38738 37-1858472 (State or Other Jurisdiction (Commission (IRS Employer
August 10, 2023	EX-99.1	Eton Pharmaceuticals, Inc. Condensed Statements of Operations (In thousands, except per share amounts) Exhibit 99.1 Eton Pharmaceuticals Reports Second Quarter 2023 Financial Results ● Total Q2 revenue of $12.0 million and net income of $4.6 million ● Product sales and royalty revenue of $6.5 million up 175% from Q2 2022 and 22% from Q1 2023 ● $21.6 million of cash on hand ● Launched Betaine Anhydrous ● Management to hold conference call today at 4:30pm ET DEER PARK, Ill., August 10, 2023 (GLOBE NE
July 5, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 30, 2023 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 30, 2023 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) File
June 28, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 28, 2023 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 28, 2023 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) File
June 28, 2023	EX-99.1	Eton Pharmaceuticals Receives Complete Response Letter (CRL) for Dehydrated Alcohol Injection Exhibit 99.1 Eton Pharmaceuticals Receives Complete Response Letter (CRL) for Dehydrated Alcohol Injection DEER PARK, Ill., June 28, 2023 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response
June 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 9, 2023 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 9, 2023 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of incorporation) (Commission File Number) (I.R.S. E
June 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 13, 2023 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 13, 2023 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of incorporation) (Commission File Number) (I.R.S.
May 11, 2023	EX-99.1	● Product sales and royalty revenue of $5.3 million up 144% from Q1 2022 and 52% from Q4 2022 ● Launched Betaine Anhydrous ● Management to hold conference call today at 4:30pm ET Exhibit 99.1 Eton Pharmaceuticals Reports First Quarter 2023 Financial Results ● Product sales and royalty revenue of $5.3 million up 144% from Q1 2022 and 52% from Q4 2022 ● Launched Betaine Anhydrous ● Management to hold conference call today at 4:30pm ET DEER PARK, Ill., May 11, 2023 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceuti
May 11, 2023	10-Q	UNITED STATES- SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES- SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 11, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Eton Pharmaceuticals UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Eton Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38738 37-1858472 (State or Other Jurisdiction (Commission (IRS Employer of
May 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 10, 2023 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 10, 2023 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State (Commission (I.R.S. Employer of incorporation) File
May 10, 2023	EX-99.1	— Eton Cares patient support program offers $0 co-pay to eligible, commercially insured patients* — — Product is now available exclusively through Optime Care — Exhibit 99.1 Eton Pharmaceuticals Announces Commercial Availability of Betaine Anhydrous for Oral Solution — Eton Cares patient support program offers $0 co-pay to eligible, commercially insured patients* — — Product is now available exclusively through Optime Care — DEER PARK, Ill., May 10, 2023 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focu
May 1, 2023	CORRESP	Eton Pharmaceuticals, Inc. 21925 W. Field Parkway, Suite 235 Deer Park, Illinois 60010-7208 May 1, 2023 Eton Pharmaceuticals, Inc. 21925 W. Field Parkway, Suite 235 Deer Park, Illinois 60010-7208 May 1, 2023 Via EDGAR Submission Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Arzhang Navai Re: Eton Pharmaceuticals, Inc. Registration Statement on Form S-3 SEC File No. 333-271196 Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act of 1933, as amende
April 27, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
April 12, 2023	LETTER	LETTER United States securities and exchange commission logo April 12, 2023 Sean Brynjelsen President and Chief Executive Officer Eton Pharmaceuticals, Inc.
April 7, 2023	EX-4.3	Form of Preferred Stock Certificate. Exhibit 4.3 Eton Pharmaceuticals, Inc. and [ ], Trustee INDENTURE Dated as of [ ], 20[ ] Cross-Reference Table Between Trust Indenture Act of 1939 and Indenture. Section of Trust Indenture Act of 1939, as amended Section of Indenture Section 310 (a)(1) 5.09 (a)(2) 5.09 (a)(3) NOT APPLICABLE (a)(4) NOT APPLICABLE (a)(5) 5.09 (b) 5.08 Section 311 (a) 5.13 (b) 5.13 Section 312 (a) 3.06 (b) 3.06 (c) 3
April 7, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-3 (Form Type) Eton Pharmaceuticals, Inc.
April 7, 2023	S-3	As filed with the Securities and Exchange Commission on April 7, 2023 As filed with the Securities and Exchange Commission on April 7, 2023 Registration No.
April 7, 2023	EX-1.2	Controlled Equity Offering℠ Sales Agreement, dated April 7, 2023, between the Company and Cantor Fitzgerald & Co. EX-1.2 2 ex1-2.htm Exhibit 1.2 Eton Pharmaceuticals, Inc. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement April 7, 2023 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Eton Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent
March 21, 2023	S-8	As filed with the Securities and Exchange Commission on March 20, 2023 As filed with the Securities and Exchange Commission on March 20, 2023 Registration No.
March 21, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table S-8 (Form Type) Eton Pharmaceuticals, Inc.
March 16, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38738 ETON PHARMACEUT
March 16, 2023	EX-99.1	Eton Pharmaceuticals, Inc. Statements of Operations (In thousands, except per share amounts) Exhibit 99.1 Eton Pharmaceuticals Reports Fourth Quarter 2022 Financial Results ● Q4 2022 revenue of $8.5 million ● Q4 Product sales and royalty revenue up 220% from prior year and 9% from Q3 ● Q4 positive net income ● Management to hold conference call today at 4:30pm ET DEER PARK, Ill., MARCH 16, 2023 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innov
March 16, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 Eton Pharmaceutica UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 Eton Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38738 37-1858472 (State or Other Jurisdiction (Commission (IRS Employer o
March 16, 2023	EX-10.6	Offer Letter Agreement by and between the Registrant and James Gruber, dated as of March 25, 2022. Exhibit 10.6
March 15, 2023	EX-99.1	— Product is targeting a rare pediatric endocrinology condition — — Potential for NDA submission in Q2 2024 — Exhibit 99.1 Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600 — Product is targeting a rare pediatric endocrinology condition — — Potential for NDA submission in Q2 2024 — DEER PARK, Ill., March. 15, 2023 (GLOBE NEWSWIRE) — Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing
March 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 15, 2023 Date of Report (Date of earliest event reported) ETON PHARMACEUTICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 15, 2023 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State (Commission (I.R.S. Employer of incorporation) Fil
March 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 13, 2023 Date of Report (Date of earliest event reported) ETON PHARMACEUTICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 13, 2023 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) Fil
March 1, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 1, 2023 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of incorporation) (Commission File Number) (I.R.S.
January 20, 2023	SC 13G/A	ETON / Eton Pharmaceutcials, Inc. / Opaleye Management Inc. Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* ETON PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29772L108 (CUSIP Number) James Silverman, One Boston Place, 26th Floor, Boston, MA 02108 (Name, Address and Te
January 11, 2023	EX-99.1	Eton Pharmaceuticals Announces FDA Acceptance of NDA Response for Dehydrated Alcohol Injection — Product previously granted orphan drug designation for methanol poisoning — — Application assigned a PDUFA date of June 27, 2023 — Exhibit 99.1 Eton Pharmaceuticals Announces FDA Acceptance of NDA Response for Dehydrated Alcohol Injection — Product previously granted orphan drug designation for methanol poisoning — — Application assigned a PDUFA date of June 27, 2023 — DEER PARK, Illinois – January 11, 2023 – Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on develop
January 11, 2023	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 11, 2023 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) F
December 28, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 28, 2022 Date of Report (Date of earliest event reported) ETON PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 28, 2022 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of incorporation) (Commission File Number) (I.R
November 10, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Eton Pharmaceut UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Eton Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38738 37-1858472 (State or Other Jurisdiction (Commission (IRS Employe
November 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38738 ETON
November 10, 2022	EX-99.1	Eton Pharmaceuticals, Inc. Condensed Statements of Operations (In thousands, except per share amounts) Exhibit 99.1 Eton Pharmaceuticals Reports Third Quarter 2022 Financial Results DEER PARK, Ill., November 10, 2022 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended September 30, 2022. “Our third quar
September 13, 2022	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 13, 2022 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State (Commission (I.R.S. Employer of incorporation)
September 13, 2022	EX-99.1	Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution -- Expected to be accretive to 2023 earnings -- Exhibit 99.1 Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution - Expected to be accretive to 2023 earnings - DEER PARK, Illinois ? September 13, 2022 ? Eton Pharmaceuticals (?Eton? or ?the Company?) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today ann
August 15, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 10, 2022 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of incorporation) (Commission File Number) (I.R.S
August 11, 2022	EX-10.1	Asset Purchase Agreement by and among the Company and Dr. Reddy’s Laboratories S.A., dated as of June 24, 2022. Exhibit 10.1 CONFIDENTIAL Note: Certain identified information has been excluded from this Exhibit because it is both not material and is the type that the registrant treats as private or confidential. Omitted information is indicated with the following: [*] ASSET PURCHASE AGREEMENT THIS ASSET PURCHASE AGREEMENT (this ?Agreement?) dated as of June 24, 2022 (the ?Effective Date?), is entered into b
August 11, 2022	EX-99.1	Eton Pharmaceuticals, Inc. Condensed Statements of Operations (In thousands, except per share amounts) Exhibit 99.1 Eton Pharmaceuticals Reports Second Quarter 2022 Financial Results DEER PARK, Ill., August 11, 2022 (GLOBE NEWSWIRE) ? Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the second quarter ended June 30, 2022. ?The second quarter of 2022 was a critic
August 11, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38738 ETON PHARM
August 11, 2022	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 Eton Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38738 37-1858472 (State or Other Jurisdiction (Commission (IRS Employer
July 18, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 18, 2022 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State (Commission (I.R.S. Employer of incorporation) File
June 24, 2022	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 24, 2022 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of incorporation) (Commission File Number) (I.R.S.
June 24, 2022	EX-99.1	Eton Pharmaceuticals Announces Sale of Hospital Products Exhibit 99.1 Eton Pharmaceuticals Announces Sale of Hospital Products ? Eton sold its rights in Biorphen?, Rezipres?, and Cysteine Hydrochloride products for total payments of up to $50 million ? Going forward, Eton?s commercial portfolio will exclusively focus on products that treat rare diseases ? Eton?s royalty portfolio is now eligible to receive up to $70 million in future milestone payments
June 14, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 14, 2022 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of incorporation) (Commission File Number) (I.R.S.
May 27, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 27, 2022 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) File
May 12, 2022	EX-99.1	Eton Pharmaceuticals, Inc. Condensed Statements of Operations (In thousands, except per share amounts) Exhibit 99.1 Eton Pharmaceuticals Reports First Quarter 2022 Financial Results DEER PARK, Ill., May 12, 2022 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the first quarter ended March 31, 2022. ?We are proud to report our fifth straight q
May 12, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38738 ETON PHAR
May 12, 2022	EX-10.1	exhibit 10.1 Exhibit 10.1 CREDIT AGREEMENT among ETON PHARMACEUTICALS, INC., as Borrower, SWK FUNDING LLC, as Agent, Sole Lead Arranger and Sole Bookrunner, and the financial institutions party hereto from time to time as Lenders Dated as of November 13, 2019 Table of Contents Page Section 1 Definitions; Interpretation. 1 1.1 Definitions 1 1.2 Interpretation 15 Section 2 Credit Facility. 15 2.1 Term Loan Commi
May 12, 2022	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 Eton Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38738 37-1858472 (State or Other Jurisdiction (Commission (IRS Employer of
April 28, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
April 11, 2022	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 11, 2022 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of incorporation) (Commission File Number) (I.R.S.
April 11, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2022 ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of incorporation) (Commission File Number) (I.R.S
April 11, 2022	EX-99.1	Eton Pharmaceuticals Appoints James Gruber as Chief Financial Officer Exhibit 99.1 Eton Pharmaceuticals Appoints James Gruber as Chief Financial Officer DEER PARK, Ill., April 11, 2022 (GLOBE NEWSWIRE) ? Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of James Gruber as Chief Financial Officer, effective immediately. He succeeds Wils
April 11, 2022	EX-99.1	Eton Pharmaceuticals Announces FDA Approval of Cysteine Hydrochloride Injection Exhibit 99.1 Eton Pharmaceuticals Announces FDA Approval of Cysteine Hydrochloride Injection DEER PARK, Ill., April 11, 2022 (GLOBE NEWSWIRE) ? Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for
April 8, 2022	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 05, 2022 ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of incorporation) (Commission File Number) (I.R.S
March 16, 2022	EX-99.1	Eton Pharmaceuticals, Inc. Statements of Operations (In thousands, except per share amounts) Exhibit 99.1 Eton Pharmaceuticals Reports Fourth Quarter 2021 Financial Results - Fourth Quarter 2021 Revenue of $6.1 million - Fourth Quarter 2021 Net Income of $1.0 million and EPS of $0.04 DEER PARK, Ill., Mar. 16, 2022 (GLOBE NEWSWIRE) ? Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today r
March 16, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38738 ETON PHARMACEUT
March 16, 2022	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2022 Eton Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38738 37-1858472 (State or Other Jurisdiction (Commission (IRS Employer o
March 14, 2022	EX-99.1	Eton Pharmaceuticals and XGen Pharmaceuticals DJB Announce Commercial Launch of Rezipres® (ephedrine hydrochloride), a Ready-to-Use Formulation of Injectable Ephedrine (4.7 mg/mL) Exhibit 99.1 Eton Pharmaceuticals and XGen Pharmaceuticals DJB Announce Commercial Launch of Rezipres? (ephedrine hydrochloride), a Ready-to-Use Formulation of Injectable Ephedrine (4.7 mg/mL) DEER PARK, Ill., Mar. 14, 2022 (GLOBE NEWSWIRE) ? Eton Pharmaceuticals, Inc. (Nasdaq: ETON) and XGen Pharmaceuticals DJB, Inc. today announced the commercial availability of Rezipres? (ephedrine hydrochlorid
March 14, 2022	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 14, 2022 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of incorporation) (Commission File Number) (I.R.S.
January 28, 2022	SC 13D/A	ETON / Eton Pharmaceutcials, Inc. / Imprimis Pharmaceuticals, Inc. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (AMENDMENT NO. 1) (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) Under the Securities Exchange Act of 1934 Eton Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 29772L 108 (CUSIP Nu
January 24, 2022	SC 13G/A	ETON / Eton Pharmaceutcials, Inc. / Opaleye Management Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* ETON PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29772L108 (CUSIP Number) James Silverman, One Boston Place, 26th Floor, Boston, MA 02108 (Name, Address and Telephone Number of Person A
December 21, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 21, 2021 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation)
December 20, 2021	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 20, 2021 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of incorporation) (Commission File Number) (I.R
December 20, 2021	EX-99.1	Eton Pharmaceuticals and ANI Pharmaceuticals Announce Commercial Availability of Carglumic Acid Tablets, the First and Only FDA-Approved Generic Version of Carbaglu Exhibit 99.1 Eton Pharmaceuticals and ANI Pharmaceuticals Announce Commercial Availability of Carglumic Acid Tablets, the First and Only FDA-Approved Generic Version of Carbaglu? (carglumic acid) ? Product is now available exclusively through Anovo specialty pharmacy ? Product is stable at room temperature while Carbaglu? requires refrigeration ? Eton Cares patient support program will offer $0 co
December 14, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 14, 2021 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of incorporation) (Commission (I.R.S. Employer
November 16, 2021	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form N-SAR For Period Ended: September 30, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR For the Trans
November 16, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38738 ETON
November 15, 2021	EX-99.1	Eton Pharmaceuticals, Inc. Condensed Statements of Operations (In thousands, except per share amounts) Exhibit 99.1 Eton Pharmaceuticals Reports Third Quarter Financial Results DEER PARK, Ill., Nov. 15, 2021 (GLOBE NEWSWIRE) ? Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the third quarter ended September 30, 2021. ?Over the last month we have made tremendous
November 15, 2021	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 15, 2021 Date of Report (Date of earliest event reported): Eton Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State or Other Jurisdiction (Commission (IRS Employe
November 15, 2021	EX-99.1	Eton Pharmaceuticals Announces Co-Promotion Agreement with Tolmar Pharmaceuticals for ALKINDI SPRINKLE Exhibit 99.1 Eton Pharmaceuticals Announces Co-Promotion Agreement with Tolmar Pharmaceuticals for ALKINDI SPRINKLE? - Tolmar?s 62-person sales force will co-promote ALKINDI SPRINKLE? to pediatric endocrinologists - DEER PARK, Ill., Nov. 15, 2021 (GLOBE NEWSWIRE) ? Eton Pharmaceuticals, Inc (Nasdaq: ETON) today announced that it has entered into a multi-year agreement with Tolmar Pharmaceuticals,
November 15, 2021	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 15, 2021 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of incorporation) (Commission File Number) (I.R
November 8, 2021	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 8, 2021 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of incorporation) (Commission File Number) (I.R.
November 8, 2021	EX-99.1	Eton Pharmaceuticals, Inc. and Azurity Pharmaceuticals, Inc. Announce FDA Approval of EPRONTIA™ (topiramate) oral solution Exhibit 99.1 Eton Pharmaceuticals, Inc. and Azurity Pharmaceuticals, Inc. Announce FDA Approval of EPRONTIA? (topiramate) oral solution The first and only FDA-approved ready-to-use liquid topiramate DEER PARK, Ill, and WOBURN, MA, Nov. 8, 2021 (GLOBE NEWSWIRE)?Eton Pharmaceuticals, Inc (Nasdaq: ETON) and Azurity Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA)
October 28, 2021	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 28, 2021 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State (Commission (I.R.S. Employer of incorporation) F
October 28, 2021	EX-99.1	Eton Pharmaceuticals Announces Acquisition of Approved Orphan Drug Product Carglumic Acid Exhibit 99.1 Eton Pharmaceuticals Announces Acquisition of Approved Orphan Drug Product Carglumic Acid -Product is the first generic alternative to one of the highest priced pharmaceutical products in the world DEER PARK, Ill. Oct. 28, 2021 (GLOBE NEWSWIRE) ? Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare
August 16, 2021	EX-99.1	Eton Pharmaceuticals, Inc. Condensed Statements of Operations (In thousands, except per share amounts) Exhibit 99.1 Eton Pharmaceuticals Reports Second Quarter Financial Results DEER PARK, Ill., Aug 16, 2021 (GLOBE NEWSWIRE) ? Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the second quarter ended June 30, 2021. ?During the second quarter we received FDA-appro
August 16, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38738 ETON PHARM
August 16, 2021	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 16, 2021 Date of Report (Date of earliest event reported): Eton Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State or Other Jurisdiction (Commission (IRS Employer
August 6, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 6, 2021 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) Fil
June 22, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 22, 2021 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) File
June 17, 2021	SC 13G/A	ETON / Eton Pharmaceutcials, Inc. / Opaleye Management Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3) ETON PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29772L108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate
June 15, 2021	EX-99.1	Eton Pharmaceuticals Acquires U.S. and Canadian Rights to ZENEO Exhibit 99.1 Eton Pharmaceuticals Acquires U.S. and Canadian Rights to ZENEO? Hydrocortisone Autoinjector ? Expands Eton?s Adrenal Insufficiency Orphan Drug Portfolio ? ZENEO? Hydrocortisone is Expected to be the First and Only Hydrocortisone Autoinjector for Patients Requiring Emergency Hydrocortisone ? Proprietary ZENEO? Needleless Device is Covered by 24 U.S. Patents Extending as Far as 2037 DE
June 15, 2021	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 15, 2021 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State (Commission (I.R.S. Employer of incorporation) File
June 15, 2021	EX-99.1	Eton Pharmaceuticals Announces FDA Approval of Rezipres® (Ephedrine Hydrochloride Injection) Exhibit 99.1 Eton Pharmaceuticals Announces FDA Approval of Rezipres? (Ephedrine Hydrochloride Injection) DEER PARK, Ill., June 15, 2021 (GLOBE NEWSWIRE) ? Eton Pharmaceuticals, Inc (Nasdaq: ETON) today announced that the U.S. Food and Drug Administration (FDA) has approved Rezipres? (ephedrine hydrochloride injection) for the treatment of clinically important hypotension occurring in the setting
June 15, 2021	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 15, 2021 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) File
May 28, 2021	EX-99.1	Eton Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Dehydrated Alcohol Injection Exhibit 99.1 Eton Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Dehydrated Alcohol Injection DEER PARK, Ill., May 28, 2021 (GLOBE NEWSWIRE) ? Eton Pharmaceuticals, Inc (Nasdaq: ETON), today announced that the company has received a Complete Response Letter (CRL) from the U.S. Food & Drug Administration (FDA) in response to the submission of its New Drug Application (NDA) for
May 28, 2021	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 28, 2021 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State (Commission (I.R.S. Employer of incorporation) File
May 28, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 28, 2021 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State (Commission (I.R.S. Employer of incorporation) File
May 13, 2021	EX-99.1	Eton Pharmaceuticals, Inc. Condensed Statements of Operations (In thousands, except per share amounts) Exhibit 99.1 Eton Pharmaceuticals Reports Record Revenue and Earnings - First quarter 2021 revenue of $11.9 million - First quarter 2021 operating earnings of $5.4 million; EPS of $0.19 - Eton now has three commercial, revenue-generating products DEER PARK, Ill., May 13, 2021 (GLOBE NEWSWIRE) ? Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and
May 13, 2021	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 13, 2021 Date of Report (Date of earliest event reported): Eton Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State or Other Jurisdiction (Commission (IRS Employer of
May 13, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38738 ETON
April 26, 2021	DEF 14A	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
April 13, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2021 ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of incorporation) (Commission File Number) (I.R.S
April 9, 2021	424B3	1,320,000 Shares Eton Pharmaceuticals, Inc. Filed Pursuant to 424(b)(3) Registration Number: 333-240252 PROSPECTUS SUPPLEMENT (To Prospectus dated August 25, 2020) 1,320,000 Shares Eton Pharmaceuticals, Inc.
April 8, 2021	EX-1.1	Underwriting Agreement, dated as of April 8, 2021, by and among the Reporting Person, the Issuer and National Securities Corporation (incorporated herein by reference to Exhibit 1.1 to the Issuer’s Current Report on Form 8-K (File No. 001-38738), filed with the Securities and Exchange Commission on April 8, 2021). EX-1.1 2 ex1-1.htm Exhibit 1.1 ETON PHARMACEUTICALS, INC. 1,320,000 SHARES OF COMMON STOCK UNDERWRITING AGREEMENT April 8, 2021 National Securities Corporation 200 Vesey Street 25th Floor New York, NY 10281 Ladies and Gentlemen: Harrow Health, Inc., a Delaware corporation (the “Selling Stockholder”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to sell
April 8, 2021	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2021 ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of incorporation) (Commission File Number) (I.R.S.
April 7, 2021	424B3	Subject to completion, dated April 7, 2021 The information in this preliminary prospectus supplement is not complete and may be changed.
March 17, 2021	EX-99.1	Eton Pharmaceuticals Announces Appointment of Jenn Adams to its Board of Directors Exhibit 99.1 Eton Pharmaceuticals Announces Appointment of Jenn Adams to its Board of Directors DEER PARK, Ill., March 17, 2021 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has appointed Jenn Adams to its board of directors effective March 17, 2021. M
March 17, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 17, 2021 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) Fil
March 16, 2021	EX-4.6	Description of Securities of the Registrant (filed herewith). Exhibit 4.6 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Introduction Eton Pharmaceuticals, Inc. (the ?Company,? ?we,? ?us? or ?our?) has one security registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended, which is our common stock. Our common stock is listed on The Nasdaq Global Market under the
March 16, 2021	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2021 Eton Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38738 37-1858472 (State or Other Jurisdiction (Commission (IRS Employer o
March 16, 2021	EX-99.1	Eton Pharmaceuticals, Inc. Statements of Operations (in thousands, except per share amounts) Exhibit 99.1 Eton Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Financial Results DEER PARK, Ill., March 16, 2021 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2020 and prov
March 16, 2021	10-K	Annual Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38738 ETON PHARMA

ETON / Eton Pharmaceuticals, Inc. - SEC-Einreichungen, Jahresbericht, Proxy Statement

Basisstatistiken

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?